Related references
Note: Only part of the references are listed.Incidental Nonuterine High-grade Serous Carcinomas Arise in the Fallopian Tube in Most Cases Further Evidence for the Tubal Origin of High-grade Serous Carcinomas
C. Blake Gilks et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Targeted therapy in gynecologic cancers: Ready for prime time?
Muhieddine Seoud et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2015)
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial
Sandro Pignata et al.
LANCET ONCOLOGY (2014)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Reclassification of serous ovarian carcinoma by a 2-tier system
Diane C. Bodurka et al.
CANCER (2012)
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Nicoletta Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A. Soslow et al.
MODERN PATHOLOGY (2012)
Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project
Lucy Gilbert et al.
LANCET ONCOLOGY (2012)
The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant Tumors
Philippe Morice et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Effect of Screening on Ovarian Cancer Mortality The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
Saundra S. Buys et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Christina M. Nagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Calculator for ovarian carcinoma subtype prediction
Steve E. Kalloger et al.
MODERN PATHOLOGY (2011)
Testicular germ cell tumors: pathogenesis, diagnosis and treatment
Christian Winter et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Current Update on Borderline Ovarian Neoplasms
Neeraj Lalwani et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Patterns of recurrence and role of adjuvant chemotherapy in stage II-IV serous ovarian borderline tumors
Karin K. Shih et al.
GYNECOLOGIC ONCOLOGY (2010)
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
John K. Chan et al.
GYNECOLOGIC ONCOLOGY (2010)
Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study
Jean A. Hurteau et al.
GYNECOLOGIC ONCOLOGY (2010)
Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Michael H. Roh et al.
MODERN PATHOLOGY (2010)
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Gordon J. S. Rustin et al.
LANCET (2010)
Researchers find a new cancer gene and a possible link between ovarian cancer and endometriosis
[Anonymous]
WOMENS HEALTH (2010)
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Kimberly C. Wiegand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas A Clinicopathologic and Molecular Genetic Analysis
Ayse Ayhan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Histological response is not a prognostic factor after neoadjuvant chemotherapy in advanced-stage ovarian cancer with no residual disease
Jean-Guillaume Ferron et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2009)
The Role of Inhibins B and Antimullerian Hormone for Diagnosis and Follow-up of Granulosa Cell Tumors
Inge Geerts et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Lymph Node-Positive Stage IIIC Ovarian Cancer A Separate Entity?
Jonathan S. Berek
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
Michael A. Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors
P. Pautier et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites
D. M. Patterson et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Keren Levanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Serous tubal Intraepithelial carcinoma: Its potential role in primary peritoneal serous carcinoma and serous cancer prevention
Joseph W. Carlson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer
Angela Chetrit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Primary Fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
Michael J. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Management of ovarian stromal cell tumors
Nicoletta Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
N. Colombo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship
David W. Kindelberger et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
The distal fallopian tube: a new model for pelvic serous carcinogenesis
Christopher P. Crum et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2007)
Chemotherapy for advanced germ cell tumors
G. Varuni Kondagunta et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada
Harvey A. Risch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study
Jeffrey Bell et al.
GYNECOLOGIC ONCOLOGY (2006)
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma
DS Chi et al.
CANCER (2006)
Management of platinum-sensitive recurrent ovarian cancer
Jacobus Pfisterer et al.
SEMINARS IN ONCOLOGY (2006)
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome
F Medeiros et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
DK Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intrapentoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group study
JL Walker et al.
GYNECOLOGIC ONCOLOGY (2006)
Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula
S Nagao et al.
GYNECOLOGIC ONCOLOGY (2005)
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer
U Menon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Symptoms associated with diagnosis of ovarian cancer: a systematic review
CR Bankhead et al.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY (2005)
Presenting symptoms of epithelial ovarian cancer
I Lataifeh et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2005)
The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors
J Brown et al.
GYNECOLOGIC ONCOLOGY (2005)
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer
J Pfisterer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial
PB Panici et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Anatomy of pelvic and para-aortic nodal spread in patients with primary fallopian tube carcinoma
X Deffieux et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2005)
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT)
RA Huddart et al.
ANNALS OF ONCOLOGY (2005)
Long-term follow-up of women with ovarian cancer after positive second-look laparotomy
SC Dowdy et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Granulosa cell tumor of the ovary
ST Schumer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
JB Trimbos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis
RE Bristow et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study
G Zanetta et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A genetic epidemiological study of carcinoma of the fallopian tube
S Aziz et al.
GYNECOLOGIC ONCOLOGY (2001)
Survival and reproductive function after treatment of malignant germ cell ovarian tumors
G Zanetta et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group
M Markman et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Paclitaxel-based chemotherapy in carcinoma of the Fallopian tube
ML Gemignani et al.
GYNECOLOGIC ONCOLOGY (2001)
Share Paper
